Related Experiment Videos
Idiopathic short stature in children
Bradley S Miller1, Donald Zimmerman
1University of Minnesota, USA.
Pediatric Annals
|April 2, 2004
Summary
Idiopathic short stature (ISS) in children often leads to shorter adult heights and social disadvantages. Growth hormone (GH) therapy is proven effective and safe for improving final height in ISS patients.
Area of Science:
- Pediatrics
- Endocrinology
- Genetics
Background:
- Idiopathic short stature (ISS) is diagnosed when growth failure cannot be attributed to identifiable causes.
- Individuals with ISS face social and physical disadvantages due to reduced stature.
- Natural history studies indicate untreated ISS results in significantly shorter adult heights.
Purpose of the Study:
- To evaluate the efficacy and safety of growth hormone (GH) therapy in children with ISS.
- To provide evidence supporting GH treatment despite the lack of defined biochemical criteria for ISS.
- To explore potential future therapeutic strategies for specific ISS subgroups.
Main Methods:
- Review of natural-history studies on untreated ISS.
- Analysis of numerous clinical trials, including placebo-controlled studies, on GH therapy for ISS.
- Assessment of the safety profile of recombinant human GH (rhGH) treatment.
Main Results:
- GH therapy demonstrates a strong positive effect on final adult height in children with ISS.
- The benefits of GH treatment are comparable to those observed in other non-GH-deficient conditions.
- rhGH treatment is considered relatively safe, despite its high cost.
Conclusions:
- GH treatment should be considered for children with ISS, irrespective of etiological uncertainty or diagnostic limitations.
- Further research into the specific causes of poor growth in ISS may enable personalized treatment approaches.
- Future therapies might include Insulin-like Growth Factor 1 (IGF-1) or IGF-1/IGFBP-3 combinations for specific patient subgroups.